Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism

Journal of Viral Hepatitis

Volumn 22, Issue 2, 2015, Pages 164-172

  Akamatsu, S ^a,b,c   Hayes, C N ^a,b   Tsuge, M ^a,b   Murakami, E ^a,b   Hiraga, N ^a,b   Abe, H ^a,b   Miki, D ^a,b,c   Imamura, M ^a,b   Ochi, H ^a,b   Chayama, K ^a,b,c  

^a Institute of Biomedical and Health Sciences   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

Anaemia; Dose reduction; Haemoglobin; Hepatitis C virus; Sustained viral response

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; IFNL4 PROTEIN, HUMAN; INORGANIC PYROPHOSPHATASE; INTERLEUKIN DERIVATIVE; ITPA PROTEIN, HUMAN; OLIGOPEPTIDE;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INOSINE TRIPHOSPHATASE GENE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CLASSIFICATION; DRUG COMBINATION; GENETICS; GENOTYPING TECHNIQUE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; PYROPHOSPHATASES; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921438114     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12275     Document Type: Article

References (38)

1. Lavanchy D,. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl 1): 74-81.
2. Barritt ASt, Fried MW,. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology 2012; 142 (6): 1314-1323 e1.
3. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365 (11): 1014-1024.
4. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364 (25): 2417-2428.
5. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N,. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56 (1): 78-84.
6. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25): 2405-2416.
7. Ogawa E, Furusyo N, Nakamuta M, et al,. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. J Hepatol 2013; 59 (4): 667-674.
8. Belperio PS, Hwang EW, Thomas IC, Mole LA, Cheung RC, Backus LI,. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C. Clin Gastroenterol Hepatol 2013; 11 (8): 1021-1027.
9. Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H,. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepatitis 2012; 19 (2): e134-e142.
10. Hara T, Akuta N, Suzuki F, et al,. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. J Med Virol 2013; 85 (10): 1746-1753.
11. Jesudian AB, Jacobson IM,. Optimal treatment with telaprevir for chronic HCV infection. Liver Int 2013; 33 (Suppl 1): 3-13.
12. Fukuda K, Imai Y, Hiramatsu N, et al,. Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C. Hepatol Res 2013; doi: 10.1111/hepr.12229.
13. Karino Y, Ozeki I, Hige S, et al,. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepatitis 2014; 21 (5): 341-347.
14. Romero-Gomez M, Berenguer M, Molina E, Calleja JL,. Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations. J Hepatol 2013; 59 (6): 1323-1330.
15. Ogawa E, Furusyo N, Nakamuta M, et al,. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Aliment Pharmacol Ther 2013; 38 (9): 1076-1085.
16. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54 (4): 1433-1444.
17. Reesink HW, Zeuzem S, Weegink CJ, et al,. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131 (4): 997-1002.
18. Chayama K, Hayes CN, Ohishi W, Kawakami Y,. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol 2013; 48 (1): 1-12.
19. Suzuki F, Suzuki Y, Sezaki H, et al,. Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. Hepatol Res 2013; 43 (7): 691-701.
20. Kawakami Y, Suzuki F, Karino Y, Toyota J, Kumada H, Chayama K,. Telaprevir is effective given every 12 hours at 750 mg with peginterferon-alfa-2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT. Antivir Ther 2013; doi: 10.3851/IMP2706 [Epub ahead of print].
21. Fellay J, Thompson AJ, Ge D, et al,. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464 (7287): 405-408.
22. Ochi H, Maekawa T, Abe H, et al,. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010; 139 (4): 1190-1197.
23. Suzuki F, Suzuki Y, Akuta N, et al,. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011; 53 (2): 415-421.
24. D'Avolio A, De Nicolo A, Cusato J, et al,. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. Antiviral Res 2013; 100 (1): 114-119.
25. Yoshizawa H, Tanaka J, Miyakawa Y,. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology 2006; 49 (1-2): 7-17.
26. Hezode C, Forestier N, Dusheiko G, et al,. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360 (18): 1839-1850.
27. Akuta N, Suzuki F, Hirakawa M, et al,. Amino Acid Substitution in HCV Core Region and Genetic Variation near the IL28B Gene Affect Viral Dynamics during Telaprevir, Peginterferon and Ribavirin Treatment. Intervirology 2012; 55 (6): 417-425.
28. Fowell AJ, Nash KL,. Telaprevir: a new hope in the treatment of chronic hepatitis C? Adv Ther 2010; 27 (8): 512-522.
29. D'Ambrosio R, Colombo M,. Safety of direct antiviral agents in real life. Dig Liver Dis 2013; 45 (Suppl 5): S363-S366.
30. Yang D, Liang HJ, Li D, Wei X, Ma L, Jia Z,. The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials. Intern Med 2013; 52 (6): 653-660.
31. Chen EY, Sclair SN, Czul F, et al,. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Clin Gastroenterol Hepatol 2013; 11 (8): 1014-1020 e1-2.
32. Coilly A, Roche B, Dumortier J, et al,. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60 (1): 78-86.
33. Hezode C, Fontaine H, Dorival C, et al,. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59 (3): 434-441.
34. Suzuki Y, Ikeda K, Suzuki F, et al,. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58 (4): 655-662.
35. Lok AS, Gardiner DF, Lawitz E, et al,. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366 (3): 216-224.
36. Rodriguez-Torres M,. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert Rev Anti Infect Ther 2013; 11 (12): 1269-1279.
37. Jacobson IM, Gordon SC, Kowdley KV, et al,. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368 (20): 1867-1877.
38. Akuta N, Suzuki F, Seko Y, et al,. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. J Med Virol 2013; 85 (6): 1028-1036.